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Abstract
Aims/hypothesis Insulin resistance and type 2 diabetes are
associated with mitochondrial dysfunction. The aim of the
present study was to test the hypothesis that oxidative
phosphorylation and electron transport capacity are dimin-
ished in the skeletal muscle of type 2 diabetic subjects, as a
result of a reduction in the mitochondrial content.
Materials and methods The O2 flux capacity of permeabil-
ised muscle fibres from biopsies of the quadriceps in
healthy subjects (n=8; age 58±2 years [mean±SEM]; BMI
28±1 kg/m
2; fasting plasma glucose 5.4±0.2 mmol/l) and
patients with type 2 diabetes (n=11; age 62±2 years; BMI
32±2 kg/m
2; fasting plasma glucose 9.0±0.8 mmol/l) was
measured by high-resolution respirometry.
Results O2 flux expressed per mg of muscle (fresh
weight) during ADP-stimulated state 3 respiration was
lower (p<0.05) in patients with type 2 diabetes in the
presence of complex I substrate (glutamate) (31±2 vs
43±3 pmol O2 s
−1 mg
−1) and in response to glutamate +
succinate (parallel electron input from complexes I and II)
(63±3vs 85±6 pmol s
−1 mg
−1). Further increases in O2 flux
capacity were observed in response to uncoupling by
FCCP, but were again lower (p<0.05) in type 2 diabetic
patients than in healthy control subjects (86±4 vs 109±8
pmol s
−1 mg
−1). However, when O2 flux was normalised
for mitochondrial DNA content or citrate synthase activity,
there were no differences in oxidative phosphorylation or
electron transport capacity between patients with type 2
diabetes and healthy control subjects.
Conclusions/interpretation Mitochondrial function is nor-
mal in type 2 diabetes. Blunting of coupled and uncoupled
respiration in type 2 diabetic patients can be attributed to
lower mitochondrial content.
Keywords Diabetes.Mitochondria.Skeletalmuscle
Abbreviations
FCCP carbonylcyanide-4-(trifluoromethoxy)-
phenylhydrazone
mtDNA mitochondrial DNA
Introduction
It has been reported that insulin resistance is associated
with mitochondrial dysfunction in several tissues. While
mitochondria are considered central to altered metabolic
pathways, leading to pathogenic processes in type 2
diabetes, the mechanisms by which mitochondrial function
contributes to the disease remain to be elucidated. Whether
it is insulin resistance per se, chronic hyperglycaemia, or
accumulation of intracellular lipid and associated alterations
in metabolic pathways that affect mitochondrial function, or
vice versa, is also unclear.
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capacity in type 2 diabetes has been provided by findings
of reduced oxidative enzyme levels [1–4] and mismatches
between glycolytic and oxidative enzyme activities [3, 5].
The activities of rotenone-sensitive NADH:O2 oxidoreduc-
tase and citrate synthase have been shown to be reduced by
40% in the skeletal muscle of type 2 diabetic patients, and
transmission electron microscopy has revealed that these
mitochondria have a reduced size and an altered morphol-
ogy [1, 6]. A decrease in the expression of genes involved
in oxidative phosphorylation has also been reported in
muscle of type 2 diabetic patients [7, 8] and men on a high-
f a td i e t[ 9]. It has been stated that impaired muscle
mitochondrial function is linked to excess intramuscular
lipid accumulation and reduced fatty acid oxidation defined
by rates of oxidative phosphorylation and ratios of
inorganic phosphate:phosphocreatine determined by mag-
netic resonance studies [6]. These studies suggest mito-
chondrial dysfunction in type 2 diabetes; however, to date,
no direct measurements of mitochondrial O2 flux capacity
in intact cells in human type 2 diabetes have been reported.
We hypothesised that oxidative phosphorylation and elec-
tron transport capacity are diminished in the skeletal muscle
of type 2 diabetic subjects, and that these changes are
attributable to a reduction in muscle mitochondrial content.
In the present study we tested these hypotheses by using
high-resolution respirometry to quantify oxidative phos-
phorylation and electron transport capacity in permeabilised
muscle fibres from biopsy samples of the quadriceps in
healthy subjects and patients with type 2 diabetes.
Subjects and methods
Subjects Informed consent was obtained from all subjects.
The study was conducted in accordance with the principles
of the Declaration of Helsinki, and was approved by the
local ethics committee for Frederiksberg and Copenhagen
County. Mitochondrial respiration was measured in per-
meabilised skeletal muscle fibres obtained from needle
biopsies of the vastus lateralis in men with (n=11) or
without (control; n=8) type 2 diabetes. The characteristics
of the subjects are provided in Table 1 and Fig. 1. All
subjects were in good health but classified as living a
typical Westernised sedentary lifestyle, participating only in
routine activities of daily living (walking, gardening, etc.)
and not engaged in regular structured or individualised
aerobic or strength training programmes or athletics. None
of the control subjects had a family history of diabetes and
none was receiving treatment for a disease. The diabetic
patients were treated for their diabetes with diet or oral
glucose-lowering medicine. All medications were withheld
24 h prior to the experiment. The patients with type 2
diabetes had no clinical signs of long-term diabetic
complications and were representative of patients treated
in the primary care sector.
Subjects were fasted overnight prior to the experiment.
A catheter was inserted into an antecubital vein for blood
sampling. After local anaesthesia of the skin and the
subcutis, a muscle biopsy was taken (Tru-Core; PBN-
Medicals, Stenløse, Denmark) and then a 120-min OGTT
(75 g glucose dissolved in 300 ml of water) was performed.
At t=30 min, a second muscle biopsy was taken.
A portion of the obtained muscle tissue was frozen
immediately in liquid nitrogen and stored at −80°C for later
analysis (see below), and a smaller piece (2–6 mg) was
placed onto a Petri dish on ice with 1 ml of relaxing
solution containing Ca
2+/EGTA buffer (10 mmol/l), free
calcium (0.1 μmol/l), imidazole (20 mmol/l), K
+/4-mor-
pholinoethanesulfonic acid (MES) (50 mmol/l), dithiothrei-
tol (DTT; 0.5 mmol/l), MgCl2 (6.56 mmol/l), ATP
(5.77 mmol/l), phosphocreatine (15 mmol/l), pH 7.1, and
individual fibre bundles were separated with two pairs of
sharp forceps, achieving a high degree of fibre separation.
The fibre bundles were permeabilised for 30 min in 3 ml of
ice-cold relaxing solution containing saponin (50 μg/ml)
[10]. After rinsing in respiration medium (MiR05; Oro-
boros, Innsbruck, Austria) containing sucrose (110 mmol/l),
Table 1 Characteristics of the
subjects
Data are means±SEM.
*p<0.05 vs control subjects
Type 2 diabetic subjects
(n=11)
Control subjects
(n=8)
Age (years) 62±2 58±1
Height (cm) 177±3 179±1
BMI (kg/m
2) 32±2* 28±1
Time since diagnosis (years) 5±2 –
Fasting insulin (pmol/l) 61±9* 34±6
Fasting glucose (mmol/l) 9.0±0.5* 5.4±0.1
Complex I activity (nmol min
−1 mg protein
−1) 50.8±6.0 58.3±4.7
Citrate synthase activity (pmol mg
−1 s
−1) 1.6±0.1 2.0±0.2
mtDNA (copies/μg tissue) ×10
3 119±7* 147±12
mtDNA/genomic DNA 2,773±252 3,030±185
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MgCl2.6H2O (3 mmol/l), taurine (20 mmol/l), KH2PO4
(10 mmol/l), HEPES (20 mmol/l), sucrose (110 mmol/l),
BSA (1 g/l), pH 7.1, the muscle bundles were blotted and
measured for wet weight in a balance controlled for
constant relative humidity, so that all biopsy samples were
hydrated to the same degree. The muscle bundles were then
immediately transferred into a respirometer (Oxygraph-2k;
Oroboros) containing air-saturated respiration medium at
37°C.
The Oxygraph-2k is a two-chamber titration-injection
respirometer with a limit of oxygen flux detection of 1 pmol
s
−1 ml
−1. The instrumentation allows for O2 flux measure-
ments with only 0.04 mg of mitochondrial protein or
1.5 mg of muscle fibres (wet weight). Standardised
instrumental and chemical calibrations were performed to
correct for back-diffusion of O2 into the chamber from the
various components, leak from the exterior, O2 consump-
tion by the chemical medium, and sensor O2 consumption
[11]. O2 flux was resolved by software capable of
converting nonlinear changes in the negative time deriva-
tive of the oxygen concentration signal.
Analysis of muscle tissue Citrate synthase activity and
complex I activity were measured spectrophotometrically
at 37°C. Citrate synthase activity was determined as
described previously [12], and complex I activity was as-
sessed by measuring the oxidation of NADH (300 μmol/l)
using ubiquinone 1 (100 μmol/l) as the acceptor. The
complex I rotenone-sensitive activity was measured by the
addition of rotenone (1 μmol/l). The protein content,
needed to calculate the specific activity, was measured
using a commercially available assay (BCA, Sigma
Chemicals, St Louis, MO, USA). For measurement of
mitochondrial DNA (mtDNA) content, DNA was isolated
from muscle biopsy samples (∼10 mg) by proteinase K
digestion at 55°C for 3 days. The 100-μl digestion mix
contained 50 mU proteinase K (PCR grade, Roche, Basel,
Switzerland), 20 mmol/l Tris-HCl (pH 8.4) and 50 mmol/l
KCl. After incubation at 80°C for 45 min, the remains were
spun down and the supernatant fraction diluted ×200 in
triethanolamine titanate (TE) plus 1 ng/μl salmon sperm
DNA (Sigma). 5 μl of this dilution was amplified in a 25 μl
PCR reaction containing 1×Quantitect SYBR Green Master
Mix (Qiagen, Hilden, Germany) and 100 nmol/l of each
primer. The amplification was monitored real-time using
the MX3000P Real-time PCR machine (Stratagene, La
Jolla, CA, USA). The primers were designed to target
genomic DNA (Forward: AGG TGC TGT CAG GAA
GCA AGG A, Reverse: TAG GGG GAG GAG GGA ACA
AGG A) or mtDNA (Forward: CCC CTG CCA TAA CCC
AAT ACC A, Reverse: CCA GCA GCT AGG ACT GGG
AGA GA). The threshold cycle (Ct) values were related to a
standard curve made with the cloned PCR products.
Respirometry protocol All measurements of respiration
were made in duplicate, simultaneously. Resting, routine
respiration (state 2, absence of adenylates) was assessed by
the addition of malate (1.5 mmol/l) and glutamate
(19 mmol/l) as the complex I substrate supply, and then
state 3 respiration was assessed by the addition of ADP
(4.8 mmol/l). The addition of succinate (9.5 mmol/l)
provided state 3 respiration with parallel electron input to
complexes I and II. The integrity of the outer mitochondrial
membrane was established by the addition of cytochrome c
(19 μmol/l); no stimulation of respiration was observed. We
examined ADP control of coupled respiration and
uncoupling control through addition of the protonophore
carbonylcyanide-4-(trifluoromethoxy)-phenylhydrazone
(FCCP) (0.7 μmol/l). The addition of rotenone (0.1 μmol/l)
resulted in inhibition of complex I for examination of O2
flux with complex II substrate alone, while antimycin A
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Fig. 1 Glucose (a) and insulin
(b) concentrations in venous
plasma before (t=0 min) and
during an OGTT. The patients
with type 2 diabetes had higher
fasting glucose levels and were
severely insulin resistant com-
pared with healthy control sub-
jects (*p<0.05). Black and
white symbols represent healthy
control subjects and patients
with type 2 diabetes,
respectively
792 Diabetologia (2007) 50:790–796(12 μmol/l) was added to inhibit complex III to observe
non-mitochondrial respiration with small contributions
from electron leak in the uncoupled state. The concen-
trations of substrates and inhibitors used were based on
prior experiments conducted for optimisation of the titration
protocols.
Data analysis All values are given as means±SEM for all
experiments, run in duplicate or triplicate. For all
statistical evaluations, a p value of less than 0.05 was
considered significant. Statistical analysis of differences in
oxygen flux between healthy control subjects and patients
with type 2 diabetes was carried out with a two-way
ANOVA for repeated measures. In the case of a significant
main effect and interaction between the variables, the
Holm-Sidak method was used for post hoc analysis. All
other comparisons between the two groups were
performed using the unpaired Student’s t test. SigmaStat
version 3.11 (Systat software, Richmond, CA, USA) was
used in all analyses.
Results
The sequential addition of substrates to the muscle tissue,
obtained from both groups before an OGTT, always
(p<0.05) resulted in a stepwise increase in state 3 O2 flux
(Fig. 2). Notably, the addition of succinate (stimulating
parallel electron input from complexes I+II) resulted in a
marked increase in O2 flux in both groups. The O2 flux per
muscle mass was significantly (p<0.05) lower in the
patients compared with the healthy subjects during complex
I and complex I+II respiration (Fig. 2). Further increases in
flux capacity and preserved significant differences between
the groups were observed with uncoupling by FCCP
(109±8 vs 86±4 pmol mg
−1 s
−1 in control and diabetic
subjects, respectively; p<0.05). Subsequent inhibition of
complex I and III with rotenone and antimycin A blunted
the O2 flux (Fig. 2). The addition of cytochrome c did not
result in significant increases in O2 flux (data not shown).
The number of copies of mtDNA and citrate synthase
activity (Table 1) indicated a lower mitochondrial density in
the patients with type 2 diabetes. The O2 flux data were
therefore recalculated relative to mtDNA content (Fig. 2b)
and citrate synthase activity (data not shown). All differ-
ences in O2 flux between patients with type 2 diabetes and
healthy control subjects disappeared following either
normalisation procedure (Fig. 2b).
The increase in O2 consumption when ADP was added
(complex I respiratory control ratio [state 3:state 2
respiration]) was not different between healthy subjects
and patients with type 2 diabetes (Fig. 3).
Mitochondrial respiration may be influenced by the
prevailing level of glucose and/or insulin. However, none
of the O2 flux rates measured with different substrates and
inhibitors displayed significant correlations with these
parameters, or the changes seen during the OGTT (data
not shown).
The glucose and insulin concentrations were markedly
increased in both groups at 30 min into the OGTT (Fig. 1).
However, the measured O2 flux in the muscle tissue obtained
at this time point deviated to a lesser extent (mean +2.4±
3.5%) from the O2 flux measured in the biopsies obtained
during fasting (data not shown).
The activity of complex I was affected by rotenone to a
similar extent in the two groups (Table 1). Furthermore, the
biochemically measured activity of complex I was signif-
icantly (p<0.02) correlated with O2 flux measured by
respirometry during rotenone inhibition (r
2=0.37).
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Fig. 2 O2 flux in permeabilised skeletal muscle fibres from patients
with type 2 diabetes and healthy control subjects. Data are shown as
O2 flux per mg of tissue (a) and further normalised to the number of
copies of mtDNA per μgo ft i s s u e× 1 0 , 0 0 0( b). When data are
expressed relative to mtDNA, any difference between the groups
disappears. Data are means±SEM (*p<0.05). Black and white bars
represent healthy control subjects and patients with type 2 diabetes,
respectively
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The primary novel findings in this study are that: (1) ADP-
stimulated state 3 mitochondrial O2 flux capacity with
electron flux through either complex I or II, or with parallel
electron input through both complexes I and II, is
substantially reduced in type 2 diabetic patients when
expressed per unit mass of skeletal muscle; and (2) when
O2 flux is normalised for mitochondrial DNA content or
citrate synthase activity, levels of both oxidative phosphor-
ylation and electron transport capacity are similar to those
observed in age-matched healthy control subjects. These
results provide direct experimental evidence for normal
function of muscle mitochondria in type 2 diabetes and do
not support other investigations reporting mitochondrial
dysfunction in diabetes. The reduced mitochondrial capac-
ity per unit muscle mass observed in this study is consistent
with the concept of reduced mitochondrial content and
volume, oxidative enzyme levels, mtDNA and decreased
levels of co-regulators of mitochondrial biogenesis-such as
peroxisome proliferator-activated receptor-γ coactivator-1
(PGC-1), nuclear respiratory factor (NRF-1 and NRF-2)
and mitochondrial transcription factor A (mtTFA)-in insu-
lin-resistant states, as found in some [7, 8] but not all
studies [13]. Therefore, it could be argued that specific
cellular signals that alter levels of mitochondria, and thus
reduce electron transport (and oxidative phosphorylation
capacity) per unit muscle mass, contribute to a variety of
aberrant metabolic pathways, including intracellular fat
accumulation, insulin resistance and glucose intolerance.
The various substrate and inhibitor titrations employed
in this study permitted an examination of various steps of
oxidative phosphorylation and electron transport under
resting respiration and maximally ADP-stimulated O2 flux
by ADP (state 3). Both resting (state 2) and ADP-
stimulated (state 3) coupled respiration were substantially
reduced (18–28%) in diabetic subjects, as was uncoupled
O2 flux with parallel electron supply from both NADH
(complex I) and FADH2 (complex II). These responses
indicate a blunting of oxidative phosphorylation linked to
ATP synthase and a decreased maximal electron flux
capacity in the uncoupled state induced by addition of
FCCP, respectively. The key finding, however, is that these
values are comparable with those in healthy control
subjects when they are normalised for mtDNA content or
citrate synthase activity, both of which are used as indices
of mitochondrial density per unit muscle mass. The 30%
reduction in state 3 O2 flux capacity per mg of muscle in
diabetic subjects with parallel electron input (glutamate +
malate + succinate) suggests an attenuation of cellular
VO2max. While the prevailing view is that O2 delivery is a
factor that influences whole-body maximal O2 consump-
tion, it remains to be determined if, and to what extent, the
observed decrement in muscle state 3 mitochondrial O2 flux
capacity in diabetic patients contributes to the lower
systemic VO2max and substrate utilisation.
The patients with type 2 diabetes were in a chronic
hyperglycaemic state and were clearly insulin resistant, but
even so, mitochondrial function/mtDNA was not impaired.
Furthermore, mitochondrial function was also measured in
the biopsy samples obtained 30 min into the OGTT, at a
time when both glucose and insulin were markedly
increased (Fig. 1). This acute metabolic perturbation did
not have any significant effect on mitochondrial respiration
in any of the subjects (data not shown).
It has been proposed that chronic hyperglycaemia
associated with insulin resistance results in the alteration
of several metabolic pathways [14]. A central hypothesis
involving the mitochondria focuses on an effect of hyper-
glycaemia providing increased reducing equivalents to the
electron transport chain, resulting in a higher membrane
potential, with consequent flow of electrons between
coenzyme Q and complex III, forming superoxides in the
mitochondrial matrix. Excess superoxide production can
induce damage to mitochondrial structures, including
several electron transport complexes, the mitochondrial
lipid bilayer and mtDNA. A role for excess superoxide
production is supported by findings of reduced glutathione
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Fig. 3 a Respiratory control
ratio for complex I (NADH
supply from substrates
glutamate + malate) measured as
the ratio of O2 flux with (state 3)
and without (state 2) ADP.
b Electron transport capacity
measured as O2 flux after
FCCP-induced uncoupling rela-
tive to coupled O2 flux at state 3
with malate + glutamate + ADP
+ succinate (parallel electron
input into both complex I and
II). No significant difference
between the groups was noted.
Data are means±SEM
794 Diabetologia (2007) 50:790–796and metallothionein antioxidant defence systems in type 2
diabetic subjects [15]. The results of this study do not
preclude these concepts, but rather suggest the possibility
that many pathogenic pathways associated with mitochon-
drial function in cellular energetics may result from
conditions leading to a reduced number of mitochondria,
which in turn could place the existing mitochondria under
stress with subsequent production of reactive O2 species,
impaired metabolism of intracellular lipids, and glucose
uptake.
It is well known that exercise training increases
mitochondrial content in skeletal muscle [16–19], and
recent work has provided evidence for increased levels of
transcriptional regulators of mitochondrial biogenesis in
response to exercise [20, 21]. In addition, physical training
can play a significant role in the prevention of insulin
resistance and type 2 diabetes [22–25]. Physical training
also substantially improves skeletal muscle insulin sensi-
tivity in patients with overt type 2 diabetes [26], and many
cellular adaptations responsible for the effect of training on
insulin sensitivity in skeletal muscle have been described
[27–31]. The cellular and mitochondrial changes in re-
sponse to exercise training occur in parallel. In obese
insulin-resistant subjects, exercise training has been shown
to increase the percentage of skeletal muscle fibre volume
occupied by mitochondria [32]. Thus, the present data
support the hypothesis that type 2 diabetes is, to a large
extent, a lifestyle disease, with insufficient exercise-induced
gene expression and a surplus of energy intake contributing
to its pathogenesis. Accordingly, studies on the effects of
‘de-training’ have provided evidence of reduced mitochon-
drial content. After cessation of an endurance training
program, citrate synthase and succinate dehydrogenase
activities in human muscle have been shown to decline
with a half-time of only 12–14 days [33]. Cytochrome c
protein concentration in rat muscles declines with a half-life
of only 7–8 days [34], and the activity in human muscles
has a half-time of similar magnitude. These decreases in the
activities of cytochrome c and succinate dehydrogenase do
not exactly follow the detraining decline in VO2max [35].
Taken together, these studies support the notion that lack of
physical activity lowers mitochondrial concentration. The
independent influences of exercise training and detraining,
hyperglycaemia, intramuscular lipid accumulation and
obesity on mitochondrial function remain to be elucidated.
In this study, the ability of the mitochondria to respond
with increased O2 consumption following the addition of
ADP, represented by the respiratory control ratio, was
preserved in the diabetic muscle (Fig. 3). Thus, this index
of mitochondrial phosphorylation capacity and coupling of
electron transport to phosphorylation indicates that the
respiratory chain of the mitochondria in type 2 diabetic
subjects functions in a similar manner to that in the
mitochondria in control subjects. This view is supported
by similar data reported 40 years ago, albeit mostly from
patients with ‘juvenile diabetes’ [36]. Similarly, an increase
(1.3–1.4 fold) in O2 flux was seen in response to
uncoupling by FCCP (Fig. 3). The fact that the increase
was similar in the two groups also testifies that electron
transport capacity is not impaired in type 2 diabetes, and
that the phosphorylation system (adenine nucleotide trans-
porter, phosphate transporter and ATP synthase) exerts
control over electron transport in patients and control
subjects to the same degree.
In conclusion, the results of the present study provide the
first direct evidence of normal mitochondrial function in the
skeletal muscle of type 2 diabetic subjects. An apparent
impairment of oxidative phosphorylation and electron
transport capacity is fully accounted for by a diminished
mitochondrial content in the diabetic muscle.
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